These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 30678050)

  • 21. Analysis of the functional WT1-specific T-cell repertoire in healthy donors reveals a discrepancy between CD4(+) and CD8(+) memory formation.
    Schmied S; Gostick E; Price DA; Abken H; Assenmacher M; Richter A
    Immunology; 2015 Aug; 145(4):558-69. PubMed ID: 25882672
    [TBL] [Abstract][Full Text] [Related]  

  • 22. WT1 as a novel target antigen for cancer immunotherapy.
    Oka Y; Tsuboi A; Elisseeva OA; Udaka K; Sugiyama H
    Curr Cancer Drug Targets; 2002 Mar; 2(1):45-54. PubMed ID: 12188920
    [TBL] [Abstract][Full Text] [Related]  

  • 23. T-cell responses directed against multiple HLA-A*0201-restricted epitopes derived from Wilms' tumor 1 protein in patients with leukemia and healthy donors: identification, quantification, and characterization.
    Rezvani K; Brenchley JM; Price DA; Kilical Y; Gostick E; Sewell AK; Li J; Mielke S; Douek DC; Barrett AJ
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8799-807. PubMed ID: 16361568
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of a WT1 protein-derived peptide, WT1, as a HLA-A 0206-restricted, WT1-specific CTL epitope.
    Li Z; Oka Y; Tsuboi A; Fujiki F; Harada Y; Nakajima H; Masuda T; Fukuda Y; Kawakatsu M; Morimoto S; Katagiri T; Tatsumi N; Hosen N; Shirakata T; Nishida S; Kawakami Y; Udaka K; Kawase I; Oji Y; Sugiyama H
    Microbiol Immunol; 2008 Nov; 52(11):551-8. PubMed ID: 19090835
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells.
    May RJ; Dao T; Pinilla-Ibarz J; Korontsvit T; Zakhaleva V; Zhang RH; Maslak P; Scheinberg DA
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4547-55. PubMed ID: 17671141
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cancer immunotherapy targeting Wilms' tumor gene WT1 product.
    Sugiyama H
    Expert Rev Vaccines; 2005 Aug; 4(4):503-12. PubMed ID: 16117707
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sensitive detection of rare antigen-specific T cells directed against Wilms' tumor 1 by FluoroSpot assay.
    Danielzik T; Koldehoff M; Buttkereit U; Beelen DW; Horn PA; Lindemann M
    Leuk Lymphoma; 2018 Feb; 59(2):490-492. PubMed ID: 28573960
    [No Abstract]   [Full Text] [Related]  

  • 28. [Cancer antigen WT1-targeting treatment for the malignancies].
    Oka Y; Kawase I
    Nihon Rinsho Meneki Gakkai Kaishi; 2008 Oct; 31(5):375-82. PubMed ID: 18974621
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia.
    Scheibenbogen C; Letsch A; Thiel E; Schmittel A; Mailaender V; Baerwolf S; Nagorsen D; Keilholz U
    Blood; 2002 Sep; 100(6):2132-7. PubMed ID: 12200377
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Co-introduced functional CCR2 potentiates in vivo anti-lung cancer functionality mediated by T cells double gene-modified to express WT1-specific T-cell receptor.
    Asai H; Fujiwara H; An J; Ochi T; Miyazaki Y; Nagai K; Okamoto S; Mineno J; Kuzushima K; Shiku H; Inoue H; Yasukawa M
    PLoS One; 2013; 8(2):e56820. PubMed ID: 23441216
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enhancement of the antigen-specific cytotoxic T lymphocyte-inducing ability in the PMDC11 leukemic plasmacytoid dendritic cell line via lentiviral vector-mediated transduction of the caTLR4 gene.
    Iwabuchi M; Narita M; Uchiyama T; Iwaya S; Oiwa E; Nishizawa Y; Hashimoto S; Bonehill A; Kasahara N; Takizawa J; Takahashi M
    Mol Med Rep; 2015 Aug; 12(2):2443-50. PubMed ID: 25936433
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Novel DNA Vaccine Platform Enhances Neo-antigen-like T Cell Responses against WT1 to Break Tolerance and Induce Anti-tumor Immunity.
    Walters JN; Ferraro B; Duperret EK; Kraynyak KA; Chu J; Saint-Fleur A; Yan J; Levitsky H; Khan AS; Sardesai NY; Weiner DB
    Mol Ther; 2017 Apr; 25(4):976-988. PubMed ID: 28237837
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antigen-specific cellular immunotherapy of leukemia.
    Van Driessche A; Gao L; Stauss HJ; Ponsaerts P; Van Bockstaele DR; Berneman ZN; Van Tendeloo VF
    Leukemia; 2005 Nov; 19(11):1863-71. PubMed ID: 16121214
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Transduction of a novel HLA-DRB1*04:05-restricted, WT1-specific TCR gene into human CD4+ T cells confers killing activity against human leukemia cells.
    Katsuhara A; Fujiki F; Aoyama N; Tanii S; Morimoto S; Oka Y; Tsuboi A; Nakajima H; Kondo K; Tatsumi N; Nakata J; Nakae Y; Takashima S; Nishida S; Hosen N; Sogo S; Oji Y; Sugiyama H
    Anticancer Res; 2015 Mar; 35(3):1251-61. PubMed ID: 25750272
    [TBL] [Abstract][Full Text] [Related]  

  • 35. WT1 peptide vaccine as a paradigm for "cancer antigen-derived peptide"-based immunotherapy for malignancies: successful induction of anti-cancer effect by vaccination with a single kind of WT1 peptide.
    Oka Y; Tsuboi A; Fujiki F; Li Z; Nakajima H; Hosen N; Shirakata T; Nishida S; Oji Y; Kawase I; Sugiyama H
    Anticancer Agents Med Chem; 2009 Sep; 9(7):787-97. PubMed ID: 19538172
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of effector antigen-specific T cells by intradermal administration of heme oxygenase-1 inducers.
    Simon T; Pogu J; Rémy S; Brau F; Pogu S; Maquigneau M; Fonteneau JF; Poirier N; Vanhove B; Blancho G; Piaggio E; Anegon I; Blancou P
    J Autoimmun; 2017 Jul; 81():44-55. PubMed ID: 28342735
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recognition of a natural WT1 epitope by a modified WT1 peptide-specific T-cell receptor.
    Tamanaka T; Oka Y; Fujiki F; Tsuboi A; Katsuhara A; Nakajima H; Hosen N; Nishida S; Lin YH; Tachino S; Akatsuka Y; Kuzushima K; Oji Y; Kumanogoh A; Sugiyama H
    Anticancer Res; 2012 Dec; 32(12):5201-9. PubMed ID: 23225417
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development of a Wilms' tumor antigen-specific T-cell receptor for clinical trials: engineered patient's T cells can eliminate autologous leukemia blasts in NOD/SCID mice.
    Xue SA; Gao L; Thomas S; Hart DP; Xue JZ; Gillmore R; Voss RH; Morris E; Stauss HJ
    Haematologica; 2010 Jan; 95(1):126-34. PubMed ID: 19679884
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Wilms tumor gene peptide-based immunotherapy for patients with overt leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosis.
    Oka Y; Tsuboi A; Murakami M; Hirai M; Tominaga N; Nakajima H; Elisseeva OA; Masuda T; Nakano A; Kawakami M; Oji Y; Ikegame K; Hosen N; Udaka K; Yasukawa M; Ogawa H; Kawase I; Sugiyama H
    Int J Hematol; 2003 Jul; 78(1):56-61. PubMed ID: 12894852
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Naive human T cells are activated and proliferate in response to the heme oxygenase-1 inhibitor tin mesoporphyrin.
    Burt TD; Seu L; Mold JE; Kappas A; McCune JM
    J Immunol; 2010 Nov; 185(9):5279-88. PubMed ID: 20921523
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.